The FDA made a special announcement about its decision, describing the news as "a major advance for public health."

This is a Class I recall, which means using the device “may cause serious injuries or death.” However, the FDA emphasized that this is a correction and not a product removal.

Two new studies evaluated the long-term impact of choosing TAVR when low-risk patients present with severe aortic stenosis. 

The shields can significantly reduce radiation exposure, according to cardiologist David G. Rizik, MD. He said they also allow cardiologists, nurses and other cath lab employees to provide care without wearing lead aprons. 

The FDA-approved technology developed by HeartFlow can predict a patient's long-term risk of target vessel failure as well as more invasive treatments performed inside a cath lab. 

Diet sodas made with artificial sweeteners are associated with an even higher risk of issues than sugar-sweetened sodas.

When Boston Scientific’s coronary DCB gained approval in the United States, it was a moment the country's cardiologists had been looking forward to for years. The cardiologists who researched the device have now detailed their findings, highlighting the "unmet need" this technology is addressing. 

President Joe Biden signed a funding bill worth $460 billion on March 9, but it only included partial relief for cardiologists, cardiac surgeons and other cardiology professionals. 

The portable device uses HeartBeam's patented 3D vectorelectrocardiography (3D VECG) technology to capture signals from three different projections and deliver a synthetic 12-lead ECG.